The global cancer biologics market size was valued at USD 130.7 billion in 2025 and is projected to grow from USD 139.46 billion in 2026 to USD 234.29 billion by 2034, registering a CAGR of 6.7% during the forecast period from 2026 to 2034. North America dominated the cancer biologics market with a market share of 41.6% in 2025.
Cancer biologics are medicines made from living organisms or biological materials and used to prevent, diagnose, or treat cancer. They include monoclonal antibodies, immunotherapies, cancer vaccines, and other targeted biological therapies. These treatments can help the immune system recognize cancer cells or target specific molecules involved in cancer growth.
Download a Free Sample To learn more about this report,
The cancer biologics market is increasingly moving toward targeted therapies, immunotherapy, antibody-drug conjugates, and cell-based treatments. Manufacturers are focusing on therapies that can selectively target cancer cells or activate the patient’s immune system while improving treatment outcomes. Advances in precision medicine are also encouraging the development of biomarker-driven therapies for specific cancer subtypes. In 2025, the FDA approved multiple innovative oncology biologics and expanded indications for existing therapies, reflecting continued development in this area.
The cancer biologics market is also witnessing growing interest in antibody-drug conjugates and combination therapies. These approaches combine targeted biological mechanisms with established cancer treatments to improve therapeutic effectiveness. In December 2025, the FDA approved trastuzumab deruxtecan with pertuzumab for first-line treatment of HER2-positive metastatic breast cancer, highlighting continued expansion of targeted biologic treatment options.
The rising prevalence of cancer and increasing demand for targeted treatment options are driving the cancer biologics market. Biologics such as monoclonal antibodies, immunotherapies, and growth factors can target specific cancer-related mechanisms and support more personalized treatment approaches. Advances in biotechnology, biomarker testing, and precision medicine are also encouraging pharmaceutical companies to develop therapies for specific cancer types and patient populations.
High treatment costs and complex manufacturing requirements are major restraints for the cancer biologics market. Biologic medicines generally require specialized production facilities, advanced quality-control systems, and sophisticated distribution infrastructure. Their high prices can also create affordability and reimbursement challenges for patients and healthcare systems. Regulatory requirements for manufacturing consistency and product safety can further increase development and commercialization costs.
Growing adoption of immunotherapy, antibody-drug conjugates, and cell-based therapies is creating significant opportunities in the cancer biologics market. Researchers and pharmaceutical companies are increasingly developing treatments that combine targeted biological mechanisms with other therapeutic approaches. Expanding biomarker testing is also creating opportunities for personalized biologics designed for patients with specific molecular characteristics.
Complex clinical development, treatment resistance, safety concerns, and manufacturing challenges remain important challenges for the cancer biologics market. Cancer is highly heterogeneous, and patients may respond differently to the same biologic therapy. Some treatments can also cause immune-related or other serious adverse effects, requiring careful monitoring. Maintaining consistent quality during large-scale biologic manufacturing further increases operational complexity.
Monoclonal Antibodies Segment Dominated the Market with a 58.7% Share in 2025
The monoclonal antibodies segment dominated the global cancer biologics market with a 58.7% share in 2025, accounting for USD 76.72 billion. Its leading position is supported by the widespread use of monoclonal antibodies in targeted cancer treatment, where they can recognize specific proteins or markers associated with cancer cells. Increasing adoption of precision medicine and continued development of antibody-based therapies are further supporting segment growth.
The growth factor segment is expanding due to its use in supporting patients undergoing cancer treatment, particularly by helping manage treatment-related complications. the blood and blood products segment continues to support oncology care through transfusion and supportive treatment applications. the vaccines and toxoids segment is also gaining attention as research and development activities continue to explore preventive and therapeutic approaches in cancer treatment.
Request Customizationto receive a tailored report.
Speak to an Analystto discuss market opportunities.
North America cancer biologics market accounted for 41.6% of the global market, reaching USD 54.37 billion in 2025, and is projected to grow at a CAGR of 7.42% during the forecast period. Growth is driven by the high prevalence of cancer, strong healthcare infrastructure, increasing adoption of targeted therapies, and substantial investments in oncology research and development. Growing use of monoclonal antibodies, immunotherapies, and precision medicine continues to strengthen regional market growth.
The US market was valued at approximately USD 47.85 billion in 2025, making it the largest contributor in North America. Increasing adoption of targeted biologics, advanced cancer treatments, immunotherapies, and precision medicine, along with strong pharmaceutical research and development activities, continues to support market growth.
Canada's market reached approximately USD 6.52 billion in 2025. Rising cancer treatment demand, expanding access to biologic therapies, increasing oncology research, and growing adoption of targeted and personalized treatments continue to support market expansion.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe cancer biologics market accounted for 27.3% of the global market, reaching USD 35.68 billion in 2025, and is projected to grow at a CAGR of 7.18% during the forecast period. Growth is supported by increasing cancer incidence, expanding access to advanced biologic therapies, and growing investments in oncology research and precision medicine. Increasing adoption of monoclonal antibodies and other targeted treatments continues to strengthen regional market demand.
The UK market was valued at approximately USD 8.92 billion in 2025. Increasing adoption of targeted cancer therapies, immunotherapies, advanced diagnostics, and personalized treatment approaches continues to support market growth.
Germany's market reached approximately USD 10.70 billion in 2025. Strong healthcare infrastructure, increasing cancer treatment demand, advanced pharmaceutical research, and growing adoption of biologic and targeted therapies continue to drive market expansion.
Asia Pacific cancer biologics market accounted for 22.4% of the global market, reaching USD 29.28 billion in 2025, and is projected to register the fastest CAGR of 9.36% during the forecast period. Growth is driven by increasing cancer prevalence, expanding healthcare infrastructure, rising healthcare expenditure, and improving access to advanced oncology treatments. Growing pharmaceutical investments and increasing adoption of targeted biologics and precision medicine are further supporting regional market growth.
Japan's market was valued at approximately USD 5.86 billion in 2025. Rising demand for advanced cancer treatments, an aging population, strong healthcare infrastructure, and increasing adoption of targeted biologics and immunotherapies continue to support market growth.
China's market reached approximately USD 17.57 billion in 2025, making it one of the largest contributors in Asia Pacific. Increasing cancer prevalence, expanding healthcare access, growing pharmaceutical investments, and rising adoption of biologics and advanced oncology therapies continue to accelerate market growth.
Middle East and Africa cancer biologics market accounted for 3.6% of the global market, totaling USD 4.71 billion in 2025, and is anticipated to grow at a CAGR of 6.94% during the forecast period. Growth is driven by increasing cancer burden, improving healthcare infrastructure, expanding access to advanced therapies, and rising investments in oncology care. Growing awareness and adoption of targeted cancer treatments are further supporting regional market expansion.
The UAE market was valued at approximately USD 0.47 billion in 2025. Increasing healthcare investments, development of advanced oncology facilities, growing adoption of targeted therapies, and rising demand for innovative cancer treatments continue to strengthen market growth.
Africa's market reached approximately USD 4.24 billion in 2025. Increasing cancer prevalence, improving healthcare infrastructure, expanding access to oncology treatments, and growing investments in cancer diagnosis and treatment continue to create growth opportunities across the region.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Flow Cytometry Market Size, Share, Growth, Analysis, Report, 2034
Gene Synthesis Market Size, Share, Growth, Analysis, Report, 2034
Cell Surface Markers Detection Market Size, Share, Growth, 2034
Single-Use Assemblies Market Size, Share, Growth, Analysis, 2034
Cancer Microbiome Sequencing Market Size, Share, Growth, 2034
Inhaled Biologics Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com